Navigation Links
Shire Engages Palio
Date:1/22/2008

Palio Named Agency of Record for FOSRENOL(R)

SARATOGA SPRINGS, N.Y., Jan. 22 /PRNewswire-FirstCall/ -- Palio, an inVentiv Health (Nasdaq: VTIV) company, is pleased to announce that Shire Pharmaceuticals (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) has engaged Palio as agency of record to lead the professional advertising and promotion for Shire's FOSRENOL, which is part of Shire's renal business unit.

"We are excited to put our team's experience and insight to work on behalf of this important product. And, we look forward to becoming a true marketing partner with Shire's FOSRENOL team," said Mike Myers, president of Palio.

Shire is a global specialty biopharmaceutical company with US operations headquartered in Chester County, Pennsylvania, just outside of Philadelphia.

"Palio's initial concept work on FOSRENOL demonstrated a level of strategic thinking and creativity that was unmatched. Their focus on the brand, their medical insight, and their commitment to our business has raised our expectations," said Joe Schlitz, vice president, US commercial lead, renal business unit, Shire Pharmaceuticals. "At Shire, our mission is to develop and market medicines that improve the quality of life for patients and their caregivers. We're looking forward to working with Palio in achieving our vision."

Palio, a full-spectrum advertising and communications agency headquartered in Saratoga Springs, NY, excels in brand creation that changes the way people think with execution that will Never be forgotten(SM). For more information on Palio, visit http://www.palio.com.

About SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), and gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent that opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the United States or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's Web site: http://www.shire.com.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 275 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.


'/>"/>
SOURCE Palio
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... According to world renowned ... definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or radiation. ... be made. , New technology has enabled doctors to administer higher doses of ...
(Date:5/2/2016)... , May 2, 2016 ... that its technology partner Mannin Research Inc. will be ... (ARVO), which takes place from May 1-5, 2016 in ... will be meeting with its vendors and research partners. ... business development goals and other collaborative opportunities for the ...
(Date:5/2/2016)... ... 02, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher ... Remote Desktop modules to its flagship X-Win32 PC X server. The new modules ... the user’s PC over encrypted SSH. , Traditionally, users of PC X servers deploy ...
(Date:4/29/2016)... ... ... The MIT bioLogic design team has won multiple A' Design Awards ... be applied to fabric and formed into living interfaces between body and environment. They ... The team harvested Natto cells and applied them to fabric with custom 3D printers.The ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/18/2016)... --> --> ... & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection ... border security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, ... defence & security companies in the border security ...
Breaking Biology News(10 mins):